News Details
08 December 2014

Neuropathic Pain Project Licensed by Signal Pharma

Signal Pharma has licensed a joint University of Aberdeen / University of Toronto programme for the treatment of neuropathic and inflammatory pain

A second project from the Kosterlitz Centre for Therapeutics has been licensed by Signal Pharma: cannabinoid receptor type 1 (CB1) allosteric enhancers for the treatment of different types of pain, for which existing treatments (opiates and NSAIDs) are generally ineffective.  Signal has licensed a patent from the Universities of Toronto and Aberdeen featuring new compounds (CB1 PAMs) which have shown impressive potential in pre-clinical studies.  Signal has provided the matched funding for a successful Canadian Institutes of Health Proof of Principle Phase II application.


back



In This Section

Search News

Search News

Browse by Month

2015

2015

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

2014

2013